The risk of hypoglycemia is lower with SGLT2 inhibitors than with conventional antidiabetic agents, but there is a higher risk of genital infections (mostly mycoses on the external genitals) [16–18, 22, 24, 26, 32]. The gene discussed is SLC5A2; the disease is Hypoglycemia.